Please use this identifier to cite or link to this item:
Title: Brentuximab vedotin: targeting CD30 as standard in CTCL.
Epworth Authors: Prince, Miles
Other Authors: Gautam, Ashish
Kim, Youn
Keywords: ALCANZA Study
Cutaneous T-Cell Lymphoma
Brentuximab Vedotin
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Feb-2018
Publisher: Impact Journals
Citation: Oncotarget. 2018 Feb 10;9(15):11887-11888
Abstract: Editorial
DOI: 10.18632/oncotarget.24472
PubMed URL:
ISSN: 1949-2553
Journal Title: Oncotarget
Type: Letter
Copyright holder: 2018 Prince et al.
Affiliated Organisations: Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum
The University of Melbourne, VIC, Australia
Appears in Collections:Cancer Services

Files in This Item:
File Description SizeFormat  
Prince et al 2018.pdf662.04 kBAdobe PDFView/Open

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.